129 Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD): Primary Analysis of a Phase II Trial
David A. Palma(Western University), Christopher J. Ryerson(University of British Columbia), Srinivas Raman(Princess Margaret Cancer Centre), Stephen Harrow(Beatson West of Scotland Cancer Centre), Stewart Gaede(London Health Sciences Centre), Brock Debenham(University of Alberta), George Rodrigues(London Health Sciences Centre), Christopher W. Goodman, Alexander V. Louie(London Health Sciences Centre), Andrea Bezjak(Princess Margaret Cancer Centre), Inderdeep Dhaliwal(Western University), Pencilla Lang(London Health Sciences Centre), Houda Bahig(Centre Hospitalier de l’Université de Montréal), Édith Filion(Centre Hospitalier de l’Université de Montréal), Adele Duimering(University of Alberta), Meredith Giuiliani, Julie Morisset(Centre Hospitalier de l’Université de Montréal), Marie‐Pierre Campeau(Centre Hospitalier de l’Université de Montréal), Joanna Laba(London Health Sciences Centre), Toni Vu, Andrew Warner(London Health Sciences Centre), Benjamin H. Lok(University Health Network), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Andrew Hope(University of Toronto)
Cited by 0
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k